Search Results

SVV-001 + Ipi-Nivo in Patients With Poorly Differentiated (NEC) or Well-Differentiated High-Grade (NET) << Back SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET) IDENTIFIER ( ClinicalTrials.gov ) : NCT06889493 DRUG/TREATMENT : Nivolumab and Ipilimumab PHASE : 1 STATUS : Recruiting SPONSOR : Aman Chauhan, MD https://www.youtube.com/watch?v=dQ-xBFvXK1E Dr. Aman Chauhan at the Sylvester Comprehensive Cancer Center, University of Miami, discusses SVV-001 + Ipi-Nivo in Patients With Poorly Differentiated (NEC) or Well-Differentiated High-Grade (NET) tumors. Click here to download this transcript >>> DESCRIPTION: The purpose of this study is to determine: The highest dose of the trial intervention that targets neuroendocrine tumors and is tolerated by patients. The highest frequency of dosing of the trial intervention that targets neuroendocrine tumors and is tolerated by patients. The highest dose and frequency of dosing of the trial intervention that targets neuroendocrine tumors with at least the same degree of effectiveness and tolerability as currently available (standard of care) treatments for patients with neuroendocrine tumors. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. STUDY CONTACT Name: Peter Hosein, MD Phone Number: 1 (305) 243-3462 Email: PHosein@med.miami.edu STUDY CONTACT BACKUP Name: Nailet Real Bestard, MS Phone Number: 1 (305) 243-8173 Email: nxr518@med.miami.edu

In Memory Of Dr. Richard R.P. Warner A Pioneer, A Relentless Advocate, & Beloved by the NET Community. Dr. Richard R.P. Warner, a pioneering physician, global authority on neuroendocrine cancer, and steadfast advocate for patients, passed away at the age of 97 on June 15, 2025, in Denver, Colorado. His passing marks the end of an extraordinary era in neuroendocrine oncology—one that he helped define and elevate through a lifetime of groundbreaking research, compassionate care, and visionary leadership. Dr. Warner’s legacy is vast, stretching from early discoveries in carcinoid syndrome to the global standards of care used today. While serving as a captain in the U.S. Air Force medical corps from 1955 - 1957, he identified the first two known cases of carcinoid syndrome caused by lung tumors—an unprecedented finding that helped define a new class of neuroendocrine cancers (Neuroendocrine Tumors or NETs) and fueled future advances in diagnostics and treatment. A gifted scholar, Dr. Warner graduated from Horace Mann School at age 15, earned his MD from the University of Cincinnati, and completed training in internal medicine and gastroenterology at Mount Sinai Hospital, followed by an NIH research fellowship. In 1963, he joined the Mount Sinai faculty, and in 1968, he founded the Carcinoid Cancer Foundation (CCF) to advance awareness and research for NETs, a field then largely unknown. Dr. Warner’s clinical and academic impact continued to grow throughout his long career. In 2006, he was a founding member of the North American Neuroendocrine Tumor Society (NANETS). A year later, he was appointed Professor of Medicine (Gastroenterology) at the Icahn School of Medicine at Mount Sinai, where he led the Center for Carcinoid and Neuroendocrine Tumors and established the Serotonin Research Laboratory. Under his direction, the center became a nationally recognized hub for excellence in diagnosis, treatment, and research. His pioneering work in therapies like PRRT, imaging advancements, and biomarker testing transformed patient care and cemented his legacy as a visionary in the field. Among Dr. Warner’s many groundbreaking contributions: He pioneered the use of somatostatin analogs to control symptoms and slow tumor growth. He was instrumental in introducing Peptide Receptor Radionuclide Therapy (PRRT) to the U.S. long before it became widely available. He helped develop and validate imaging techniques such as octreotide scans and Ga-68 PET. He refined laboratory testing, including the use of 5-HIAA for diagnosis and monitoring of carcinoid syndrome. He authored or co-authored over 100 peer-reviewed publications, clinical reviews, and textbook chapters. But Dr. Warner’s influence extended far beyond academic and clinical achievements. He was beloved by patients for his ability to explain complex conditions with clarity and kindness, and for always making time to listen. For many, seeing Dr. Warner was the first time they felt truly seen—by a doctor who not only understood their rare condition but cared deeply about their quality of life. He also played a vital role in mentoring generations of physicians, fostering a new wave of clinicians who continue to approach NETs with the empathy and scientific rigor he championed. As a global thought leader, Dr. Warner was a sought-after speaker and educator, presenting at major conferences such as the European Neuroendocrine Tumor Society (ENETS), the North American Neuroendocrine Tumor Society (NANETS), and countless medical forums where he shared insights drawn from decades of front-line care. In 2009, Dr. Warner announced the appointment of his son, Keith R.P. Warner, as Chief Executive Officer of the Carcinoid Cancer Foundation (CCF). In March 2025, the Carcinoid Cancer Foundation announced its partnership with the Neuroendocrine Cancer Foundation, which began to take the lead on CCF’s programs. Even in his later years, Dr. Warner remained deeply involved in the community he helped build—speaking directly to patients, supporting clinical trials, and always serving as a bridge between science and the human experience. His legacy is profound: more informed patients, better treatments, earlier diagnoses, longer survivals, and most of all—more hope that all cancer will eventually be conquered. Though Dr. Warner is no longer with us, his life’s work continues in every improved outcome, every empowered patient, and every step forward in neuroendocrine cancer care. Make a Gift in Memory of Dr. Warner Read More About Dr. Richard Warner's Legacy >>>

Lu-177 DOTATATE vs Everolimus in Lung NETs << Back Randomized Phase II Trial of Lutetium Lu-177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors DRUG/TREATMENT: LUTETIUM LU-177 DOTATATE (PRRT) + (EVEROLIMUS) CLINICALTRIALS.GOV IDENTIFIER: NCT04665739 PHASE: 2 STATUS: Recruiting SPONSOR: National Cancer Institute (NCI) https://www.youtube.com/watch?v=v8Ev1_8DVdo Dr. Suki Padda Discusses Lu177 Dotatate in Lung NETs https://www.youtube.com/watch?v=Z6ky87smo-I Dr. Heloisa Soares Discusses Lu-177 Dotatate in Lung NETs DESCRIPTION: This phase II trial studies the effect of lutetium Lu-177 dotatate compared to the usual treatment (everolimus) in treating patients with somatostatin receptor positive bronchial neuroendocrine tumors that have spread to other places in the body (advanced). Radioactive drugs, such as lutetium Lu-177 dotatate, may carry radiation directly to tumor cells and may reduce harm to normal cells. Lutetium Lu-177 dotatate may be more effective than everolimus in shrinking or stabilizing advanced bronchial neuroendocrine tumors. For more information on eligibility criteria, trial locations, study details, etc. go to ClinicalTrials.gov to view this trial here. PRINCIPAL INVESTIGATORS: Thomas A. Hope, MD, UCSF Sukhmani K. Padda, MD, Cedars Sinai Medical Center, Los Angeles, California CONTACT: This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.

CDK4/6 Abemaciclib GEP-NETS << Back Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors CLINICALTRIALS.GOV IDENTIFIER: NCT03891784 DRUG/TREATMENT: abemaciclib PHASE: 2 STATUS: Recruiting SPONSOR: University of Washington Collaborator: Eli Lilly and Company https://www.youtube.com/watch?v=nzR8G_0DLQo Dr. Heloisa Soares Discusses CDK4/6 abemaciclib GEP-NETS DESCRIPTION: This phase II trial studies how well abemaciclib works in treating patients with digestive system neuroendocrine tumors that have spread to other places in the body, do not respond to treatment, and cannot be removed by surgery. Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT/Principal Investigator: David B. Zhen, MD Fred Hutch/University of Washington Cancer Consortium EMAIL : dbzhen@uw.edu

< Back to the upcoming events page https://www.youtube.com/watch?v=uCJWd8VLNsQ ABOUT A neuroendocrine cancer diagnosis can bring emotional, mental, and psychological challenges that are just as difficult as the physical ones. Join licensed clinical psychologist Dr. Karen Kersting from the Medical College of Wisconsin for a supportive discussion on Coping with Neuroendocrine Cancer: Managing Distress, Worry & Grief. She will offer insights and practical strategies to help patients and caregivers navigate the full emotional and psychological impact of living with NETs. ABOUT KAREN "REN" KERSTING Karen “Ren” Kersting, Ph.D. (she/her) Assistant Professor/Clinical Psychologist Medical College of Wisconsin Surgery/Surgical Oncology Karen Kersting, PhD, is a licensed clinical psychologist who provides counseling and psychotherapy to patients treated by surgeons in the Division of Surgical Oncology at the Medical College of Wisconsin. She completed an undergraduate degree in Journalism at the University of Wisconsin—Madison, a PhD in Counseling Psychology at Virginia Commonwealth University in Richmond, VA, and a postdoctoral fellowship in clinical health psychology at the Dayton Veterans Administration Medical Center in Dayton, OH. She joined the faculty of MCW in 2016. Dr. Kersting’s research interests include the development and assessment of integrated psychosocial services for people coping with cancer diagnosis and treatment, with an emphasis on patients diagnosed with cancer of the pancreas. Additionally, her work aims to highlight issues related to social determinants of health and Acceptance and Commitment Therapy interventions. SUBMIT YOUR QUESTIONS Submit your non-case specific questions for Dr. Kersting. T he opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS

< Back to the upcoming events page https://www.youtube.com/playlist?feature=share&list=PLPAgUIq-85n87MCeOUD77oRr6XQYk-mrG ABOUT The Neuroendocrine Cancer Foundation is hosting an in-person NET Educational Event for patients and caregivers in Tucson, Arizona on Saturday, March 29th, from 1:30-6:00 PM. Hear presentations from 8 NET experts. Listen to patient stories. Learn about the latest in surgery, liver-directed therapy, systemic therapy, PRRT, and clinical trials. Ask questions during the extended live question and answer session. Find out how you can spread awareness about neuroendocrine cancer. Network with other patients and caregivers in the post-event reception. There is no cost to attend. This event is made possible by the generosity of donors and sponsors. Special thanks to our host, Dr. Junaid Arshad, University of Arizona Cancer Center (UACC). This event will not be broadcast. Note: The Neuroendocrine Cancer Foundation was formerly known as LACNETS. Read the full announcement here >>> THANKS TO OUR SUPPORTERS AGENDA Time Topic Speaker 1:30 - 2 PM Check-in 2 - 2:10 PM Welcome & Introductions Neuroendocrine Cancer Foundation Team 2:10 - 2:15 PM Patient Story Kimberly, NET Patient 2:15 - 2:30 PM NETs 101: NET Terms & Concepts You Need to Know Bassam Sonbol, MD, Medical Oncologist, Mayo Clinic Phoenix 2:30 - 2:45 PM Surgery for NETs: To Cut or Not to Cut? Gagandeep Singh, MD, Surgical Oncologist, City of Hope Phoenix 2:45 - 3 PM Liver-Directed Therapy: Killing Liver Tumors Without a Big Scar Gregory Woodhead, MD, PhD, Interventional Radiologist, University of Arizona Cancer Center 3 - 3:15 PM Systemic Therapy for NETs: Treatment Options for Metastatic Tumors Heloisa Soares, MD, PhD, Medical Oncologist, Huntsman Cancer Institute 3:15 - 3:30 PM PRRT: Current & New Trends Holly Thompson, MD, MPH, Nuclear Medicine, University of Arizona Cancer Center 3:30 - 3:45 PM Break 3:45 - 3:50 PM Nursing Perspective on the Management of NETs Linda Moe, RN, University of Arizona Cancer Center 3:50 - 4:05 PM Clinical Trials: The Latest & Greatest Pamela Kunz, MD, Medical Oncologist, Yale Cancer Center 4:05 - 5 PM Q&A with Expert Panel All Faculty - Moderated by Dr. Junaid Arshad, Medical Oncologist, University of Arizona Cancer Center & Lisa Yen, LACNETS 5 - 6 PM Networking Reception ABOUT OUR SPEAKERS Dr. Junaid Arshad Medical Oncologist, University of Arizona Cancer Center (UACC) Host/Moderator/Speaker Dr. Junaid Arshad is an Assistant Professor of Medicine and our new faculty member of GI Medical Oncology. He received his medical degree from King Edward Medical University, Lahore, Pakistan. He completed his Internal Medicine Residency at St. Mary's Hospital, Waterbury, CT. He has joined the Cancer Center after his Hematology and Medical Oncology Fellowship from University of Miami, FL. Dr. Arshad is a Clinical and Translational Scientist with a focus on developing novel therapeutics for several areas of Upper GI Oncology. Dr. Arshad's Clinical and Research focus targets mainly the Upper GI Oncology including Gastrointestinal Stromal Tumors, Gastric Cancers, Esophageal Cancers and Neuroendocrine Tumors. He is a part of several clinical trials and has contributed to several peer reviewed publications. His prior research focuses on the use of biomarkers such as circulating tumor DNA (ctDNA) in the diagnosis, treatment and surveillance of Gastrointestinal Stromal Tumors. He has expanded his areas of research interest to include other disease modalities such as Neuroendocrine Cancers. Dr. Pamela Kunz Medical Oncologist, Yale Cancer Center Dr. Pamela Kunz is an Associate Professor of Medicine in the Division of Oncology at Yale School of Medicine where she also serves as the Director of the Center for GI Cancers and Division Chief of GI Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital. She received her medical degree from the Dartmouth Geisel School of Medicine. Her postgraduate training included a medical residency, chief residency, and oncology fellowship at Stanford University School of Medicine. Dr. Kunz is an international leader in the treatment and clinical research of patients with GI malignancies and neuroendocrine tumors (NETs). She holds several key leadership positions in the field including past President of the North American Neuroendocrine Tumor Society, recent past Chair of the Neuroendocrine Tumor Taskforce of the NCI and standing member of FDA’s Oncology Drug Advisory Committee. Dr. Kunz was recently appointed Editor-in-Chief of JCO Oncology Advances. In addition to her focus on NETs, she is a leading voice for promoting diversity, equity and inclusion in medicine. She served as the Vice Chief of DEI for the Section of Medical Oncology at Yale School of Medicine and in 2021. Dr. Kunz was awarded ‘Woman Oncologist of the Year’ by Women Leaders in Oncology for her work in promoting gender equity and received the 2024 'Distinguished Mentor Award' by the North American Neuroendocrine Tumor Society. X @PamelaKunzMD Linda Moe, RN Registered Nurse, University of Arizona Cancer Center (UACC) I have been an oncology nurse for 34 years, working in both inpatient and outpatient settings. My experiences range from bedside nursing, ambulatory care, ICU care, charge nurse, nurse manager, nurse navigator and RN coordinator. Currently, I am working as Dr. Arshad’s RN coordinator. I have been working specifically with GI cancers for the past seven years. I spearheaded and achieved NAPRC accreditation status at the University of Arizona Cancer Center. I have specialized in Bone Marrow Transplant, pain management, palliative care, wound care and end-of-life care. I hold a bachelor’s degree in nursing and a bachelor’s degree in naturopathy with an emphasis on wellness and cancer prevention. I am a Reiki Master with over 20 years of Reiki experience. I was selected as a “Fabulous 50” nurse in 2020 and successfully passed a law establishing “National Fatigue Awareness Day” in the state of Arkansas. Dr. Gagandeep Singh Surgical Oncologist, City of Hope Phoenix Internationally renowned liver and pancreas surgeon Gagandeep “Gaugs” Singh, M.D., F.A.C.S., is Chief of Surgical Oncology and Director of Surgical Services at City of Hope® Cancer Center Phoenix. A seasoned health care leader with more than 20 years’ experience building outstanding surgical teams, Dr. Singh is excited to return to Phoenix – where he completed part of his medical training – and to City of Hope, where he spent a decade as the chief of City of Hope Duarte’s surgical oncology program. In the clinic, Dr. Singh takes a thoughtful yet forceful approach to treating cancers of the liver, pancreas and gastrointestinal systems. As a health care leader, he is passionate about empowering teams to achieve their fullest potential. He has been recognized with numerous awards and leadership positions. After beginning his faculty academic career at the Keck School of Medicine at the University of Southern California in Los Angeles, Dr. Singh was appointed director of the Liver and Pancreas Center at the John Wayne Cancer Institute in Santa Monica, California, where he also served as chair of the Cancer Committee. At City of Hope Duarte, Dr. Singh spearheaded the liver and pancreatic cancer programs and led the Division of Surgical Oncology to national recognition. He has been included on multiple lists of “America’s Top Surgeons,” “Best Doctors of America,” “Super Doctors” and “Top Doctors of America.” Dr. Singh earned his medical degree from the Mahatma Gandhi Institute of Medical Sciences in India, before training at multiple internationally renowned cancer centers, including Tata Memorial Hospital and Cancer Center in Bombay, René Descartes University in Paris and the Royal Liverpool University Hospital in the United Kingdom, as well as the Marion Bessin Liver Center at the Albert Einstein College of Medicine in New York, Maricopa Medical Center in Phoenix and the University of Iowa. A board-certified surgeon, diplomate of the American Board of Surgery and fellow of the American College of Surgeons, Dr. Singh is an internationally recognized expert in his field and a member of the National Comprehensive Cancer Network for Hepatobiliary Cancers, the group that sets the guidelines for the standard of care for hepatobiliary cancers. As a researcher, Dr. Singh has written on topics such as complex liver resections for liver metastases, management algorithms for neuroendocrine tumors, vascular reconstructions with difficult pancreatic surgery for pancreatic cancer and advanced robotic surgery. His work on robotic surgery has been presented at the Society of Surgical Oncology, America’s Hepato-Pancreato-Biliary Association, the Society of Laparoscopic & Robotic Surgeons and other national meetings. An innovator at heart, he is in constant pursuit of enhancing the surgical experience and developing technical innovations in liver and pancreatic surgery. He has collaborated with engineers from the California Institute of Technology and Harvey Mudd College and has several invention disclosures and patents to his name. Dr. Singh’s translational research includes projects with molecular biologists, X-ray crystallographers, structural chemists and super-resolution scientists across the City of Hope national system . Dr. Heloisa Soares Medical Oncologist, Huntsman Cancer Institute Dr. Heloisa Soares is a medical oncologist who focuses on neuroendocrine cancers. She is an associate professor at the Huntsman Cancer Institute (HCI) at the University of Utah, where she is also the Medical Director for the Clinical Trials Office. Nationally, she serves as the NCI NET task force co-chair and the chair of the North American Neuroendocrine Tumor Society (NANETS) inaugural NET Patient Action Team of the NETPact Committee. She also recently served as a member of the directors for NANETS. Dr. Soares is a passionate advocate for patients. You can follow her on Twitter at @helops79 Dr. Bassam Sonbol Medical Oncologist, Mayo Clinic Phoenix Mohamad Bassam Sonbol, M.D., is an Oncologist, with special interest in neuroendocrine tumors and gastrointestinal malignancies. In addition to his clinical activities, Dr. Sonbol is active in research that focuses on investigating novel treatments including targeted therapies, immunotherapy, and other agents that could potentially help patients with neuroendocrine and gastrointestinal cancers. Dr. Sonbol focuses on the holistic treatment for cancer patients taking into consideration their medical and social aspects that have been affected by their cancer diagnosis. Dr. Holly Thompson Nuclear Medicine & Theranostics, University of Arizona Cancer Center (UACC) My passion for medicine is defined by a tenacious desire to diagnose and treat diseases that cause human suffering. Profoundly inspired by the study of cancer, I pursued research into its biology first working at the Fred Hutchinson Cancer Center and then related innovative imaging technologies working at Vitra Bioscience, following my undergraduate degree. Driven to help address cancer and other complex diseases at a more direct and personal level, I earned my Doctor of Medicine degree from the University of Miami, followed by a Masters in Public Health. After an internship in surgery at Harvard, I completed postgraduate Radiology training at UC Davis and further subspecialized in Nuclear Medicine training at Stanford University, where I learned about neuroendocrine tumors having witnessed NETTER-1 trial participants. I had the privilege of joining a large integrated healthcare provider in Northern California where I worked to enable NET patients’ early access to 177Lu-Dotatate(Lutathera, prior to FDA approval. Subsequently I became the Nuclear Medicine physician lead for regional multidisciplinary NET tumor boards facilitating patient cases to be rigorously reviewed with an integrated, patient-centered focus. Currently, as an Associate Professor at the University of Arizona, my focus is on advancing NET patient care and research, while teaching and inspiring the next generation of Nuclear Radiologist/Oncologist. It is an honor to be invited to participate in the LACNETS outreach program. Dr. Gregory Woodhead Interventional Radiology, University of Arizona Cancer Center (UACC) Gregory Woodhead, MD, PhD, joined the interventional radiology faculty at University of Arizona, with the majority of his practice focusing on interventional oncology at the University of Arizona Cancer Center. Dr. Woodhead’s career objective is to translate devices and therapies from the development stage into clinical practice. His interest in cancer cell biology draws from his PhD research on the role of the catenin-signaling pathway in cell fate decisions for progenitor and cancer cells. As a resident and fellow at the University of Arizona, he embarked on an analysis of catheter-directed mechanical thrombectomy for the treatment of acute pulmonary embolism (PE), which is a common cause of morbidity and mortality in cancer patients. He is the PI on multiple trials and registries that seek to identify long-term differences in patients who received mechanical thrombectomy for PE in comparison to those who received only anticoagulation alone. Dr. Woodhead has published over 40 papers and frequently presents at national and international meetings. He is an integral member of multiple institutional programs and a committee member for many professional societies. He is passionate about educating and mentoring medical students, residents, and fellows. He previously served as the chair of the MD/PhD admission committee.

Our Team KAVYA VELAGAPUDI, MSW Executive Director and Board Member Kavya is the Executive Director and Board Member of the Neuroendocrine Cancer Foundation. Since 2015, Kavya has been involved with the organization providing fundraising and management support. She is a fundraising and management professional with 15 years of experience generating revenue and resources for various nonprofit organizations. With a Master's in Social Welfare and a concentration in Non-Profit Administration & Policy Advocacy, Kavya has a unique blend of development, management, and clinical skills. Before launching her independent fundraising consultancy Honu Fundraising, she was the Development Director of the International Museum of Women, now part of Global Fund for Women, in San Francisco. Before joining the Museum, Kavya was the Western Region Director of Starlight Children’s Foundation in Los Angeles overseeing all development, communications, and program services in Starlight’s Western Region. Contact: Kavya@NCF.net LISA YEN, NP, NBC-HWC Director of Programs & Outreach Lisa Yen was a nurse practitioner hospitalist for over 12 years prior to her husband’s diagnosis with advanced, metastatic pancreatic NET in January 2015. She brings a unique perspective to the Neuroendocrine Cancer Foundation as a medical professional and a caregiver. Once a regional support group, LACNETS has grown into a national NET patient advocacy group that now supports the Carcinoid Cancer Foundation, founded by Dr. Richard Warner. As the Director of Programs & Outreach, Lisa curates educational content for the Neuroendocrine Cancer Foundation’s virtual and in-person events, podcasts, annual conferences and symposiums, video resource library and Clinical Trials Guide. She facilitates patient and caregiver support groups and a support line. She has developed a peer mentorship program (NETCONNECT ), a health coaching program and wellness retreats . Lisa also co-created NET VITALS with LACNETS founder Giovanna Joyce Imbesi and City of Hope’s Dr. Daneng Li. In addition to developing content, Lisa attends national and international medical and scientific conferences to stay apprised of the latest in NET advances. She collaborates with NET experts, researchers, partners and patient advocates to improve access to education and care. Her passion is to help improve the quality of life for those affected by NET. Lisa was the recipient of the 2020 Monica Warner Award. She serves as treasurer on the executive board of INCA. She is a member of the NANETS NETPact Committee . Lisa earned a BA in psychology from Wheaton College in Illinois, a BSN from Loyola University of Chicago, and an MSN from UCLA’s School of Nursing’s Acute Care Nurse Practitioner Program. Through Vanderbilt, she became a Nationally Board-Certified Health and Wellness Coach (NBC-HWC) and is currently on the Vanderbilt and VA faculty, where she trains healthcare professionals and health coach trainees. When Lisa is not serving the NET community, she enjoys spending time with her husband, Tom, and their rescue dog, Skyler. She also enjoys traveling, snowboarding, and live theater. Watch Lisa and her husband Tom describe how they made decisions in this 2017 LACNETS video. Contact: Lisa@NCF.net HEATHER DAVIS Director of Community Engagement Heather Davis initially joined the Neuroendocrine Cancer Foundation as a NETCONNECT mentor for caregivers in 2019 after finding LACNETS to be an invaluable collective of medical resources, experts and caring support. Heather has nearly 20 years of account management experience in marketing. She has also served as her mother’s primary medical advocate since her pancreatic neuroendocrine cancer diagnosis in 2012. She earned her Bachelor’s Degree in Journalism/Advertising and Sociology from San Diego State University. As the Director of Community Engagement, she is eager to expand NET awareness and connect patients, caregivers and providers through this exceptional community. She is passionate that knowledge and collaboration make all the difference in both the quality of care and the quality of life for those affected by this rare disease. Heather enjoys learning and exploring new things with her nephews and having fun with family and friends. Contact: Heather@NCF.net BOARD OF DIRECTORS DONNA GAVIN Board President Donna Gavin is the sister of LACNETS founder Giovanna Joyce Imbesi and has been a board member of GeneratePossibility.org/LACNETS (now the Neuroendocrine Cancer Foundation) since 2009. Donna is dedicated to impactful work and has many years of experience in non-profit management and leadership. With a background in finance and law, she has served on boards and constituent groups of non-profit organizations for over 20 years. She is currently a senior grants administrator and paralegal at Cold Spring Harbor Laboratory on Long Island, New York, a scientific research institution and National Cancer Institute designated Cancer Center. Donna holds a BA from Williams College and a diploma in paralegal studies from New York University. MARY DONLEVY Board member Mary Donlevy joined the LACNETS Board in 2020. She brings the patient perspective as she has been thriving despite living with pancreatic neuroendocrine tumor since 2005. She has been close friends with LACNETS Founder Giovanna Joyce since 2010 and involved with LACNETS (now Neuroendocrine Cancer Foundation) since then. Mary has served as a NET CONNECT mentor and Advisory Committee member. She has been actively involved in the monthly meetings and virtual NET support groups. Mary received her Bachelor's Degree in Communications from University of San Diego and has over 10 years of medical and sales training. Her passion is to help those dealing with this difficult diagnosis and still enjoy a very full and active life. She is the mother of four children, two of which are identical twins, born after her cancer diagnosis. Mary enjoys ocean swimming, yoga and traveling with her husband and children in her free time.

ALPHAMEDIX: Alpha PRRT with Pb-212 DOTAMTATE in NETs << Back ALPHAMEDIX - Targeted Alpha-emitter Therapy of PRRT Naive Neuroendocrine Tumor Patients CLINICALTRIALS.GOV IDENTIFIER: NCT05153772 DRUG/TREATMENT: AlphaMedix 212Pb-DOTAMTATE PHASE: 2 STATUS: Recruiting SPONSOR: Radiomedix, Inc. COLLABORATOR: Orano Med LLC https://www.youtube.com/watch?v=HECT9t4V0Ho Dr. Ebrahim Delpassand Discusses the AlphaMedix Trial (May 9, 2023) https://www.youtube.com/watch?v=3sDMIlPbepY Dr. Heloisa Soares Discusses the AlphaMedix Trial (March 10, 2023) UPDATE October 8, 2025: Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors Sanofi reported that its experimental drug AlphaMedix™ (²¹²Pb-DOTAMTATE) met all its main goals in a phase 2 clinical trial, showing real benefits in people with certain gastro-pancreatic neuroendocrine tumors, whether or not they have had prior radiation treatment. The drug was generally well tolerated, and these results will inform future talks with regulators as Sanofi works toward potential approval. Read the full press release >>> DESCRIPTION: Radiomedix is sponsoring a multicenter Phase 2 study of 212Pb-DOTAMTATE enrolling adult subjects with positive somatostatin positive neuroendocrine tumors with no prior history of peptide receptor radionuclide therapy (PRRT naive). In this open-label, multicenter, single-arm Phase 2 study, adult subjects with histologically confirmed NETs and positive somatostatin analog imaging, with no prior PRRT (PRRT naive) will be enrolled to receive 212Pb-DOTAMTATE. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT: Susan Cork EMAIL: scork@exceldiagnostics.com PHONE: 713-341-3203

Lu-177 DOTATATE + Triapine in GEP-NETs << Back Phase 2 Trial: Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors DRUG/TREATMENT: LUTATHERA (Lu-177) + Triapine CLINICALTRIALS.GOV IDENTIFIER: NCT05724108 PHASE: 2 STATUS: Recruiting SPONSOR: National Cancer Institute (NCI) https://www.youtube.com/watch?v=ptDSlj3Neao June 2024: Dr. Aman Chauhan discusses Phase 2 LUTATHERA (Lu-177) + Triapine study https://www.youtube.com/watch?v=rK0NSdorBnk April 2023: Dr. Aman Chauhan discusses Phase 2 LUTATHERA (Lu-177) + Triapine study DESCRIPTION: This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors that have spread from where they first started (primary site) to other places in the body (metastatic). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for deoxyribonucleic acid synthesis and cell growth. Lutetium Lu 177 dotatate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177 dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving triapine in combination with lutetium Lu 177 dotatate may be more effective at shrinking tumors or slowing tumor growth in patients with metastatic neuroendocrine tumors than the standard therapy of lutetium Lu 177 dotatate alone. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT/Principal Investigator: Aman Chauhan, MD EMAIL: axc3268@med.miami.edu RELATED RESOURCES Clinical Trials Using Lutetium Lu 177 Dotatate - NCI Dr. Chauhan's presentation slides can be downloaded here: Dr. Chauhan Presentation on Lu-177 DOTATATE + Triapine Trial .pptx Download PPTX • 16.18MB 2023 NANETS Abstract shows the combination of Triapine and Lu-177 DOTATATE was safe with preliminary efficacy signals.

Lanreotide + Octreotide Resources SOMATULINE DEPOT (LANREOTIDE) RESOURCES Somatuline Depot Downloadable Patient Support Guides Somatuline Depot (Lanreotide) Copay Assistance/Home Injections: Click here to learn more , OR CALL (866) 435-5677 Ipsen - GEP-NETs Network - Injection Map SANDOSTATIN LAR DEPOT (OCTREOTIDE) RESOURCES Novartis - Patient Resources Novartis - Universal Copay Program Patient Assistance Now Oncology Sandostatin LAR Depot (Octreotide) Copay Assistance: Novartis - Patient Assistance Foundation Enrollment Novartis - Universal Copay Program or call 1-800-277-2254 READ LACNETS Blog Post - "A Focus on Somatostatin Analogs (Your Monthly Shots)" LACNETS Blog Post - "The Shot" LACNETS Blog Post - "Practical Tips for Patients on the Shot Somatostatin Analog" LISTEN Podcast Episode 32: Focus on Somatostatin Analogues (SSAs)

<< Back Pancreatic NET (PNET) Insulinoma upLIFT: Ersodetug in Insulinoma/Tumor Hyperinsulinism PRRT/RLT Trials Alpha PRRT with Pb-212 (all NET) Alpha PRRT with Ac-225 (GEP-NETs only) Alpha PRRT with Pb-212 VMT Alpha PRRT with RYZ401 in PRRT-naive Solid Tumors Expressing SSTRs Lu-177 DOTATATE + M3814 (Peposertib) (GEP-NETs) Lu-177 DOTATATE + Olaparib (GEP-NETs) Lu-177 DOTATATE + Triapine (GEP-NETs) Lu-177 DOTATATE + Cabozantanib (all NET) Lu-177 DOTATATE + Sunitinib in PNETs COMPOSE (GEP-NETS) ComPareNET Lu-177 vs CAPTEM in PNETs Lu-177 DOTATATE vs Everolimus in Lung NETs NETTER-P: Lutathera in Adolescent Patients Oral Treatment SWOG S2104: Adjuvant CAPTEM for High Risk pNET Belzutifan/MK-6482 in PNET + PPGL + VHL CDK4/6 Abemaciclib Other Trials Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas BRAVESST2: CRN09682 in SST2-Expressing NENs and Other Solid Tumors IL13Rα2 CAR T Cell Study for Solid Tumor Cancers SORENTO™: Subcutaneous Octreotide for GEP-NETs Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) SORENTO™: Subcutaneous Octreotide for GEP-NETs STELLAR-311: Zanzalintinib Versus Everolimus in pNET and epNET with Locally Advanced or Metastatic Neuroendocrine Tumors Survivin Long Peptide Vaccine (SurVaxM) in Metastatic NETs Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms

Research / Clinical Trials < Back to Topics Latest News on Clinical Trials Clinical Trials News Play Video Play Video 06:31 Update on Cabozantinib Neuroendocrine Cancer Foundation Interview with Dr. Aman Chauhan • 2025 Clarification: The recent CABINET subgroup analysis presented at ESMO included thoracic NET patients (lung and thymic), with approximately 80% being lung NETs. Additionally, in the epNET cohort, about 20% of patients had lung NETs. Learn about one of the biggest breakthroughs in neuroendocrine tumor (NET) treatment: the FDA approval of Cabozantinib for metastatic NETs. In this in-depth interview, the Neuroendocrine Cancer Foundation’s Lisa Yen speaks with NET expert Dr. Aman Chauhan about the landmark CABINET clinical trial, new data from ESMO 2025, and what this means for patients with pancreatic NETs, extra-pancreatic NETs, lung NETs, and thymic NETs. Dr. Chauhan explains why Cabozantinib—a VEGF TKI targeted therapy—is transforming care for patients who often have limited treatment options, especially those with somatostatin receptor–negative lung NETs who may not qualify for somatostatin analogs (SSA) or PRRT. He also discusses promising results in higher-grade (G2–G3) well-differentiated NETs, an area with few effective treatment choices. ✔ What the CABINET trial revealed ✔ Why Cabozantinib is effective across multiple NET types ✔ How lung and thymic NET patients (thoracic NETs) benefited—~80% of the thoracic subgroup were lung NETs ✔ How this approval is changing clinical practice ✔ Introduction to Zanzalintinib (Zanza) — a next-generation VEGF TKI now entering phase 3 trials ✔ How to find NET clinical trials near you on ClinicalTrials.gov If you’re a patient, caregiver, or healthcare professional looking for new NET treatment options, this update provides essential insights into where the field is headed and how future drugs are being developed. 🔗 Search for NET clinical trials: https://www.ncf.net/clinical-trials Play Video Play Video 04:02 The Latest Advances in Neuroendocrine Cancer: An Update with Dr. Udhayvir Grewal • 2025 In this conversation, Dr. Udhayvir Grewal from the Winship Cancer Institute at Emory shares the newest developments in neuroendocrine cancer (NET/NEC) research, treatment, and clinical trials — offering clarity, progress updates, and hope for patients and caregivers in the NET community. 🔬 Key Highlights: - Alpha PRRT (Alpha Radioligand Therapy): New investigational treatments including Lead-212 Dotamtate, Lead-212 VMT-Alpha-NET, and Actinium-225 Dotatate (ACTION-1) are showing promising early results and may change the treatment landscape for NET patients. - New FDA-Approved Therapy for Pheochromocytoma & Paraganglioma: Belzutifan is now available for a subset of patients, supported by durable response data from the LITESPARK study. - Advances in High-Grade Neuroendocrine Carcinoma: Encouraging results are emerging from trials targeting DLL3, including obrixtamig, radioligand therapies, ADCs, and tri-specific drugs currently in development. 📍 Next Steps & Resources To explore active clinical trials and educational resources, visit: 🔗 NCF.net #NeuroendocrineCancer #NETCancer #NeuroendocrineTumor #CancerResearch #PRRT #ClinicalTrials #PatientEducation #NCF #NETUpdates #AlphaPRRT #DLL3 Play Video Play Video 06:26 The Latest in High-Grade Neuroendocrine Carcinoma (NEC): A Conversation with Dr. Chauhan • 2025 In this important update, Dr. Aman Chauhan shares the newest and most promising developments in treatment and research for high-grade neuroendocrine carcinoma (NEC) — a rare and aggressive form of neuroendocrine cancer. For decades, treatment options for NEC have been limited and outcomes have remained largely unchanged. Today, that reality is beginning to shift — and this conversation highlights the progress bringing renewed hope to patients and families. Highlights in This Discussion: - DLL3-targeted immunotherapy, including T-cell engagers such as tarlatamab and emerging therapies like Obrixtamig - Ongoing progress in clinical trials for high-grade NEC - Early success with radiopharmaceutical approaches targeting DLL3 - Exploration of oncolytic viruses, including the Seneca Valley Virus combined with ipilimumab (ipi) and nivolumab (nivo) - Advances in next-generation immunotherapy, including CAR-T and checkpoint combinations 📍 Want to Learn More? To explore active or upcoming clinical trials for NEC, visit the Neuroendocrine Cancer Foundation’s Clinical Trials Guide at NCF.net/clinical-trials #NeuroendocrineCancer #NEC #HighGradeNEC #ClinicalTrials #Immunotherapy #DLL3 #PatientEducation #NETCancer #NeuroendocrineTumor #CancerResearch #NCF Play Video Play Video 06:20 Dr. Jennifer Chan Shares 2025 Highlights & Future Directions in NET Research at the 2025 INCA Summit In this exclusive 2025 INCA Summit interview, Lisa Yen from the Neuroendocrine Cancer Foundation speaks with Dr. Jennifer Chan, President of NANETS and medical oncologist at Dana-Farber Cancer Institute, about the latest advances and future directions in neuroendocrine cancer research and treatment. Dr. Chan reflects on her 20-year journey in the field and highlights a pivotal year for neuroendocrine cancer care — including the FDA and EMA approvals of cabozantinib for both pancreatic and extrapancreatic NETs, and belzutifan for advanced pheochromocytomas and paragangliomas. She discusses how these breakthroughs are expanding treatment options and offering renewed hope to patients worldwide. Looking ahead, Dr. Chan shares her excitement about ongoing and upcoming clinical trials, including the COMPETE trial (PRRT vs. everolimus) and studies involving alpha-emitting PRRT agents, which may further transform clinical practice. 🎥 Highlights: Global collaboration through the International Neuroendocrine Cancer Alliance (INCA) Major new treatment approvals in 2025 (cabozantinib, belzutifan) Promising data from recent and emerging clinical trials (COMPETE, PRRT advances) A look toward the next wave of neuroendocrine cancer research 📍 Recorded live at the 2025 INCA Summit in Sofia, Bulgaria 👩⚕️ Guest: Dr. Jennifer Chan, President of NANETS 🎙️ Host: Lisa Yen, Neuroendocrine Cancer Foundation #NeuroendocrineCancer #INCA2025 #NANETS #Cabozantinib #Belzutifan #DanaFarber #OncologyResearch #PatientAdvocacy Play Video Play Video 05:29 Dr. Jennifer Chan & Dr. Del Rivero Discuss Advancing NET Research at the 2025 INCA Summit In this insightful conversation from the 2025 INCA Summit in Sofia, Bulgaria, leading neuroendocrine cancer experts Dr. Jennifer Chan (Dana-Farber Cancer Institute, USA) and Dr. Jaydira Del Rivero (National Cancer Institute, NIH) discuss the future of neuroendocrine tumor (NET) research, emphasizing the importance of clinical trials, patient engagement, and international collaboration. Dr. Del Rivero highlights the mission of INCA’s research committee—to align scientific priorities with patient needs, ensure greater patient participation in research, and develop better models and biomarkers for understanding and treating NETs. She explains the range of clinical research, from translational and molecular studies to natural history, prevention, and treatment trials, and how each contributes to improving diagnosis, therapy, and quality of life for patients. Dr. Chan underscores the vital role of patients as partners in research, helping shape meaningful endpoints and driving practice-changing discoveries like the CABINET trial, which recently led to new treatment approvals for neuroendocrine cancers. 🎥 Highlights: The mission of the INCA Research Committee Translational research and model development for NETs The value of biomarkers and molecular insights Understanding natural history studies and their role in cancer discovery Empowering patients as research partners Reflections on the impact of the CABINET study 📍 Recorded live at the 2025 International Neuroendocrine Cancer Alliance (INCA) Summit, Sofia, Bulgaria 👩⚕️ Speakers: Dr. Jennifer Chan & Dr. Jaydira Del Rivero #NeuroendocrineCancer #INCA2025 #ClinicalTrials #CancerResearch #PatientAdvocacy #DanaFarber #NIH #NANETS #CABINETTrial #OncologyResearch Play Video Play Video 05:30 Dr. Halfdanarson on ITM’s COMPETE Trial • 2025 ENETS • Neuroendocrine Cancer Foundation NANETS President Emeritus Dr. Thor Halfdanarson discussed the positive results from ITM’s Phase 3 COMPETE Trial at the 2025 ENETS Annual Medical and Scientific Conference in Krakow, Poland. The COMPETE trial was the first prospective, randomized phase 3 study comparing PRRT with an active treatment (everolimus or afinitor). For more information, visit https://www.ncf.net/clinical-trials. Play Video Play Video 05:27 Dr. Jennifer Chan Discusses Results of CABINET Trial (Cabozantinib) as Effective Treatment at ESMO24 Watch #LACNETS' exclusive view with incoming NANETS president Dr. Jennifer Chan at ESMO Congress 2024 (#ESMO24) in Barcelona, Spain, explaining the updated results of the CABINET trial evaluating Cabozantinib in Advanced Neuroendocrine Tumors. https://www.lacnets.org/post/positive-results-of-the-cabinet-trial-show-cabozantinib-as-a-new-effective-treatment-in-advanced-n Play Video Play Video 04:44 Dr. Aman Chauhan About the Most Exciting Progress in the Neuroendocrine Cancer Field @ NANETS Miami In this exclusive interview at NANETS Regional in Miami, NET expert Dr. Aman Chauhan from Sylvester Comprehensive Cancer Center shares the recent advances he's most excited about in the neuroendocrine cancer field. @SylvesterCancer @AmanChauhanMD @CarcinoidNETs @HealingNET1 @netcancerday @CureNETs @PheoPara #NETsMiami Play Video Play Video 03:51 Update: NETTER-2 Trial Supports Lutathera® as 1st Line Treatment - Dr. Singh Explains The NETTER-2 phase 3 trial results show Lutathera® may be offered as first-line treatment for newly diagnosed grade 2 and 3 advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). When compared to long-acting octreotide, Lutathera® reduced the risk of disease progression or death by 72% in patients with somatostatin receptors. “These positive results for Lutathera are practice-changing and offer new first-line treatment data for patients who have a significant unmet need. This study confirms the clinical benefit of first-line radioligand therapy (RLT) for newly diagnosed patients living with these types of advanced GEP-NETs. These findings should instill confidence among physicians in using Lutathera as a first-line treatment for patients with this life-threatening type of cancer.” — Dr. Simron Singh, NET expert, Sunnybrook Health Sciences Centre, Ontario, Canada. Read the full Novartis Press Release: https://www.novartis.com/news/media-releases/novartis-lutathera-significantly-reduced-risk-disease-progression-or-death-72-first-line-treatment-patients-advanced-gastroenteropancreatic-neuroendocrine-tumors Load More Educational Videos on Research / Clinical Trials Educational Content on Research/Clinical... Play Video Play Video 01:29:26 The Latest in Neuroendocrine Cancer Clinical Trials • 2026 NCF Event • Feb 20, 2026 Topics Covered: Neuroendocrine, NET, clinical trials, PRRT, RLT, neoadjuvant trials, adjuvant trials, metastatic NET, symptom control ABOUT Join us for an overview of the latest clinical trials in neuroendocrine cancer with Dr. Heloisa Soares, a medical oncologist and physician-scientist at the Huntsman Cancer Institute (HCI) in Salt Lake City. Dr. Soares will walk through key neuroendocrine cancer clinical trials including what they are studying, what makes them exciting, and how they may shape future treatment options. She will also explain why clinical trials matter, how they benefit patients, and what to consider when exploring whether a trial might be right for you. Whether you’re a patient, caregiver, or simply trying to stay informed, this webinar will provide clear, practical insights to help you better understand emerging research and what it means for the neuroendocrine cancer community. The presentation focuses on current NET clinical trials. For information on NEC clinical trials, go to our high grade resources page: https://www.ncf.net/high-grade-nen-resources. Visit the event page at https://www.ncf.net/events/feb2026 Play Video Play Video 27:02 9. The Future of NETs: Emerging Therapies & Clinical Trials • Dr. Aman Chauhan •2025 NET Cancer Day Dr. Aman Chauhan speaks about "The Future of NETs: Emerging Therapies & Clinical Trials" at the 2025 NET Cancer Day Symposium. The 2025 NET Cancer Day Symposium was a collaboration between the Neuroendocrine Cancer Foundation and the Sylvester Comprehensive Cancer Center, part of UHealth – University of Miami Health System, in Miami, Florida, on Sunday, November 9th. #netcancer #neuroendocrinecancer #netawareness #rarecancer #cancercommunity #advocacy #ncf #lacnets #AboveAndBeyondAward #netcancerday #cancereducation #netsupport Play Video Play Video 18:44 1. Demystifying Clinical Trials • Taymeyah Al-Toubah • 2025 NET Cancer Day Symposium Taymeyah Al-Toubah speaks on "Demystifying Clinical Trials" at the 2025 NET Cancer Day Symposium. The 2025 NET Cancer Day Symposium was a collaboration between the Neuroendocrine Cancer Foundation and the Sylvester Comprehensive Cancer Center, part of UHealth – University of Miami Health System, in Miami, Florida, on Sunday, November 9th. #netcancer #neuroendocrinecancer #netawareness #rarecancer #cancercommunity #advocacy #ncf #lacnets #AboveAndBeyondAward #netcancerday #cancereducation #netsupport Play Video Play Video 14:04 15. What Matters About Clinical Trials • Pamela Kunz, MD • @NCFCancer "What Matters About Clinical Trials" 2025 Neuroendocrine Cancer Foundation Annual Patient Conference Pamela Kunz, MD Medical Oncologist Yale Medicine @NCFCancer Play Video Play Video 01:27:39 Understanding Alpha & The Evolving PRRT Landscape • Dr. Grewal • 2025 NCF Event • September 22, 2025 The field of PRRT (Peptide Receptor Radionuclide Therapy) is evolving rapidly, and patients are hearing more about new developments like alpha therapies, the recent NETTER-2 and COMPETE trial results, and other advances. Join medical oncologist Dr. Udhayvir Singh Grewal from the Winship Cancer Institute of Emory University as he breaks down what these changes mean for people living with neuroendocrine cancer. This webinar will help patients and caregivers make sense of emerging research and therapies—and what they may mean for the future of NET treatment. For more information, visit https://www.ncf.net/events/sep2025. Play Video Play Video 33:12 "The Future of NETs: Evolving Treatments & Clinical Trials" • Jaydira Del Rivero, MD • 2024 "The Future of NETs: Evolving Treatments & Clinical Trials" with Jaydira Del Rivero, MD, Medical Oncologist/Endocrinologist, National Cancer Institute/National Institutes Of Health at the 2024 NET Cancer Day Symposium. Play Video Play Video 15:17 "The Latest in NET Medical Therapies" • Andrew Hendifar, MD, Cedars Sinai • 2024 NET Cancer Day Andrew Hendifar, MD, Medical Oncologist, Cedars Sinai, talks about the latest in NET medical therapies at the 2024 NET Cancer Day Symposium. Play Video Play Video 16:36 10. Clinical Trials: The Latest & Greatest • Pamela Kunz, MD • @NCFCancer Play Video Play Video 28:41 Clinical Trials 101/Opportunities to Access NET Resources&Trials • Del Rivero MD • 2023 NETCancerDay Clinical Trials 101/Opportunities to Access NET Resources&Trials • Del Rivero MD • 2023 NET Cancer Day Symposium • Santa Monica, CA • @NCFCancer Speaker: Jaydira Del Rivero, MD Medical Oncologist Endrocrinologist National Cancer Institute, NIH For more information, visit LACNETS.org Load More In Depth Look at Active Clinical Trials In Depth Look: Active Clinical Trials Play Video Play Video 06:46 (STELLAR-311) Zanzalintinib Versus Everolimus in pNET and epNET • ClinicalTrials.gov ID: NCT06943755 Dr. Aman Chauhan discusses (STELLAR-311) Zanzalintinib Versus Everolimus in pNET and epNET with Locally Advanced or Metastatic Neuroendocrine Tumors. Visit https://www.ncf.net/clinical-trials for more information. Play Video Play Video 14:15 Tarlatamab in DLL3-Expressing Tumors Including NEN • ClinicalTrials.gov: NCT06788938 • Dr. Goldman Join Dr. Jonathan Goldman, medical oncologist and clinical trial specialist at UCLA, as he provides an in-depth overview of a new clinical trial investigating tarlatumab, a DLL3-targeted bispecific T-cell engager designed to treat a wide range of neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). In this talk, Dr. Goldman explains: - What DLL3 is and why it is an important target found on many neuroendocrine tumors - How tarlatumab works by connecting T-cells to tumor cells to trigger a focused immune response - Why DLL3-positive tumors—including small cell lung cancer, lung carcinoids, thymic tumors, pancreatic NETs, gastrointestinal NETs, prostate NEC, Merkel cell carcinoma, and others—may respond to this therapy - The structure of the L10 Clinical Trial, now in Stage 2 and enrolling across all University of California cancer centers - What patients can expect from the tarlatumab treatment schedule and dosing - Potential side effects such as cytokine release syndrome, fatigue, constipation, loss of taste, neurologic symptoms, and tumor lysis syndrome Dr. Goldman highlights both the promise of DLL3-targeted therapies and the ongoing need to understand how DLL3 expression levels relate to patient response. For more information, visit https://www.ncf.net/clinical-trials-1/tarlatamab Play Video Play Video 13:57 A Study of ZL-1310 in Participants With Selected Solid Tumors • ClinicalTrials.gov ID: NCT06885281 Dr. Rohit Thummalapalli discusses "A Study of ZL-1310 in Participants With Selected Solid Tumors" (ClinicalTrials.gov ID: NCT06885281). For more information, visit NCF.net/clinical-trials Play Video Play Video 06:54 (CAREFNDR) Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen•NCT07087054 Dr. Aman Chauhan discusses (CAREFNDR) Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen (ClinicalTrials.gov: NCT07087054). For more information, visit https://www.ncf.net/clinical-trials Play Video Play Video 08:57 Study of 225Ac-ABD147 to Establish Optimal Dose • ClinicalTrials.gov: NCT06736418 • Dr. Chauhan Dr. Aman Chauhan discusses the Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy (ClinicalTrials.gov: NCT06736418). For more information, visit https://www.ncf.net/clinical-trials Play Video Play Video 12:34 May 19, 2025: Dr. Aman Chauhan discusses the DAREON-5 & DAREON-7 Studies DAREON-5 is a phase 2 trial studying BI 764532, an antibody-like molecule (DLL3/CD3 bispecific) that may help the immune system fight cancer. This is a clinical trial for high grade neuroendocrine cancers. It is open to adults with small cell lung cancer and other neuroendocrine cancers including extra-pulmonary neuroendocrine carcinoma and large cell neuroendocrine carcinoma. The purpose of the study is to find a suitable dose of BI 764532. The study is sponsored by Boehringer Ingelheim. For more information, visit https://www.lacnets.org/clinical-trials-1/dareontm--5%3A-dll-3-bite-for-neuroendocrine-cancers. Play Video Play Video 16:57 SVV-001 + Ipi-Nivo in Patients With Poorly Differentiated NEC or Well-Differentiated High-Grade NET Dr. Aman Chauhan at the Sylvester Comprehensive Cancer Center, University of Miami, discusses SVV-001 + Ipi-Nivo in Patients With Poorly Differentiated (NEC) or Well-Differentiated High-Grade (NET) tumors. Recorded: April 22, 2025 For more information, visit https://www.ncf.net/clinical-trials-1/svv-001 Play Video Play Video 29:35 IL13Rα2 CAR T Cell Study for Solid Tumor Cancers • Dr. Anusha Kalbasi Dr. Anusha Kalbasi from Stanford discusses the immunotherapy study using IL13Rα2 CAR T cell for the treatment of metastatic solid tumors on March 27, 2024. For more information about this trial, visit https://www.lacnets.org/clinical-trials-1/il13r%CE%B12-car-t-cell-study-for-solid-tumor-cancers. Visit the LACNETS Clinical Trials page for more information at https://www.lacnets.org/clinical-trials. Play Video Play Video 05:10 Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC • Dr. Aman Chauhan Dr. Aman Chauhan at Sylvester Comprehensive Cancer Center, University of Miami discusses the Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC. Recorded: June 20, 2024 Visit the LACNETS Clinical Trials page for more information at https://www.lacnets.org/clinical-trials. Load More Patient Stories: Clinical Trials Patient Stories: Clinical Trials Play Video Play Video 04:08 Patient Story: NET Patient shares about her experience in a clinical trial (LACNETS) NET Patient Mary shares about her experience in a clinical trial (Everolimus or Afinitor). November 7, 2020 To learn more about LACNETS, visit www.LACNETS.org. Play Video Play Video 21:23 NET Clinical Trial: An Oral Somatostatin Analogue in Patients with Carcinoid Syndrome - Jan 2024 Crinetics is sponsoring a clinical trial to evaluate the safety, pharmacokinetics (PK), and exploratory dose response of paltusotine treatment, an oral (pill) somatostatin analogue in patients with carcinoid syndrome. Learn more about the trial and inclusion criteria here. This trial is currently open at Hoag Cancer Center in Newport Beach, California with Dr. Michael Demeure. If interested, contact Clinical Research Nurse Coordinator Jericho Rabago via direct line 949-764-6796 or email Jericho.Rabago@hoag.org. Learn about more clinical trials here: lacnets.org/clinical-trials Play Video Play Video 07:10 Patient Story: NET Patient shares her experience with Alpha PRRT NET Patient DeAnne shares her experience with Alpha PRRT. March 16th, 2021 To learn more about the LACNETS , visit www.LACNETS.org. < Back to Topics Next Topic >